Коррекция костно-метаболических нарушений у больных псориатическим артритом
Диссертация
Диссертация состоит из введения, обзора литературы, описания материалов и методов, глав собственных исследований, обсуждения полученных результатов, выводов, практических рекомендация, списка литературы. Работа изложена на 127 страницах машинописного текста, включает 14 рисунков и 19 таблиц. Указатель литературы содержит 209 источников, из них 38 -отечественных и 171-зарубежных. В последние… Читать ещё >
Содержание
- Глава 1. Обзор литературы
- 1. 1. Этиология, патогенез и классификация псориатического артрита
- 1. 2. Современные представления об остеопорозе и специальные биохимические маркеры костного метаболизма
- 1. 3. Современные представления о терапии псориатического артрита
- Глава 2. Материалы и методы исследования
- Глава 3. Клиническая характеристика наблюдаемых больных
- Глава 4. Состояние костной плотности у больных псориатическим артритом в процессе лечения метотрексатом и бивалосом
- Глава 5. Состояние костного метаболизма у больных псориатическим артритом до и после проведенной терапии
- Глава 6. Клиническая эффективность комплексной терапии больных псориатическим артритом
Список литературы
- Агабабова Э.Р., Годзенко A.A., Гусева И. А. и соавт. Анкилозирующий спондилоартрит: современное состояние проблемы и вопросы классификации. Клинич. ревматол. 1997- 1: 2−8,
- Агабабова ЭР., Бадокин В. В., Эрдес Ш. Ф. и соавт. Разработка и апробация диагностических критериев псориатического артрита. Тер. архив. 1988- 12: 117−21.
- Антоньев A.A., Суворова К. Н., Башлыкова Т. М. Об общих ошибках в диагностике и лечении артропатического псориаза // Сов. медицина, — 1977.—№ 4.—С. 105—109.
- Бадокин В.В. Вторичный системный амилоидоз у больных псориатическим артритом. Научно-практич. ревматол. 2001- 4: 84−90.
- Бадокин В.В. К вопросу о классификации псориатической артропатии // Клинич. медицина.— 1995.— № 1.— С. 53—57.
- Бадокин В.В. Псориатический артрит и псориаз: проблемы взаимосвязи и взаимообусловленности. Избранные лекции по клинической ревматологии, под ред. Насонова В. А., Бунчука H.B. М. «Медицина» 2001.
- Бадокин В.В. Псориатический артрит: клиника, диагностика, лечение. Дисс. докт. мед. наук. Москва, 2003: 188−97.
- Баженов А.Н., Трусов В. В. Ревматоидный артрит и остеопороз. Клиническая медицина. 1998- 7: 15−20.
- Беляев Г. М., Ющенко А. П. О лечении больных артропатическим псориазом // Вестн. дерматол.— 1984.— № 3.— С. 41—44.
- Беневоленская Л.И., Эрдес Ш., Яковлева Д. Б. Антигены гистосовместимости при псориатическом и серонегативном ревматоидных артритах // Тер. архив.— 1986.— № 7.— С. 17—19.
- Бурдейный А.П. Сравнительная эффективность медленно действующих противоревматических препаратов при псориатическом артрите, Автореф. дисс. докт. мед. наук. М., 1995.
- Вавилов А.М., Самсонов В. А., Завалишина Л. Э. Иммуноморфологические исследования Т-лимфоцитов в коже больных псориазом. Вести, дерматол. 2000- 4: 4−5.
- Важбии Л.Б., Хлыстов Ю. А., Карлов В. В. и соавт. Псориаз^ и очаги фокальной инфекции в JIOP-органах. Вестн. дерматол. 1995- 6: 39−40.
- Варшавский В.А., Панасюк H.H., Антонов М. В., Фальковская О. В. Морфологическая характеристика псориатической нефропатии. Арх. патол. 1990- 6: 32−6.
- Васильев A.A. Лучевая диагностика изменений костей и суставов при псориазе // Автореф. дисс. канд. мед. наук.— К., 1992.— 25 с.
- Владимиров В.В., Меньшикова Л. В. Современные представления о псориазе и методы его лечения // Русс. мед. журнал.— 1989.— Т.6, № 20.— С. 1318—1323.
- Годзенко A.A., Гусева И. А., Гусейнов Н. И. Перекрестные формы серонегативных спондилоартритов // Тер. архив.— 1997. —N5.— С. 43—46.
- Довжанский-СИ., Утц СР. Псориаз и псориатическая болезнь. Изд. Саратовского университета. 1992, ч 1, 176.
- Евстафьев В.В., Шейкман А. Ш. Прогностическое значение иммунопатологических показателей- при псориазе // Росс. журн. кож. вен. болезней.— 2000.— № 1.— С. 28—30.
- Загретдинова P.M., Шараев П. Н., Колясева A.A., Шарипова З. А. Показатели обмена соединительной ткани при псориатической болезни // Вестн. дерматол.— 2002.— № 5.— С. 47—48.
- Ибрагимов Ш. И. Клинико генетический анализ артропатической и обычной форм псориаза // Автореф. дисс.канд. мед. наук.— М., 1983.— 27 с.
- Каратаев А.Е., Насонова В. А., Муравьев Ю. В. Серонегативные спондилоартриты // Тер. архив.— 1999.— № 2.— С. 26—-29.
- Клинышков И.А. Особенности кожного поражения, повышающие риск развития суставной патологии у больных псориазом, Сб. науч. работ врачей, посвященный 100-летию Отделенческой больницы на ст. Омск. Омск, 1996- 158−61.
- Корсун В.Ф., Станкевич A.B., Яговдик Н. Э. О вирусной этиологии псориаза // Вестн. дерматол.— 1999.— № 4.— С. 9—11.
- Лашииа И.Ю., Асеева Е. А., Соловьев С. К. Эффективность пульс-терапии глюкокортикостероидами и метотрексатом при ревматоидном артрите. Научно-практич. ревматол. 2000- 1: 55−60.
- Милевская С.Г. Роль кальциевого обмена и кальцийрегуляторной гормональной системы в патогенезе псориатического артрита // Автореф. дисс. канд. мед. наук.— Томск, 1991.— 36 с.
- Мылов Н.М. Спектр рентгенологических проявлений псориатического артрита и дифференциальная диагностика его в группе ревматических болезней. Вестн. Дерматол. 1992- 1:43.
- Мылов Н.М., Эрдес Ш. Ф., Мордовцев В. Н. Клинико-рентгенологическое исследование костно-суставного аппарата при обычном псориазе. Вестн. дерматол. венерол. 1988- 3:54−58.
- Насонов E. JL, Соловьев С. К. Применение метотрексата в ревматологии. М: 2000: 12−8.
- Рак С Y., Sakhaee К, Adams-Huet В. et al. Treatment of postmeaopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial // Ann. Intern. Med — 1995. — Vol. 123. — p. 401— 408
- Ремикейд. Монография по препарату. Шеринг-Плау Сентрал Ист АГ. 2005, 55 с.
- Сигидин Я.А., Лукина Г. В. Ревматоидный артрит. Москва 2001, стр.64−67.
- Соловьев С.К., Иванова М. М., Насонов E.JI. Интенсивная терапия ревматических заболеваний: Пособие для врачей. М.: МИК, 2001. -40 с.
- Трунина JI.C. Разработка дифференциально-диагностических признаков псориатического и ревматоидного артритов // Автореф. дисс. канд. мед. наук.— Mi, 1983.— 26 с.
- Шарапова Г. Я., Короткий Н. Г., Молоденков М. Н. Псориаз: иммуномеханизмы патогенеза и методы лечения Москва, 1989, стр. 220.
- Шахтмейстер И.Я., Каменных Е. В. К вопросу распространенности псориатического артрита // Вестн. дерматол.— 1990.— № 10.—С. 55—57.
- Янгуразова Д.Р., Арифжанов К. Р., Шакиров Э. А. Клинико-МРТ-диагностика некоторых серонегативных спондилоартритов // Тез. докл. конф. «Лучевая диагностика и лучевая терапия на пороге третьего тысячелетия».— М., 2000.— С. 705—707.
- Abu-Sharka М., Gladman D.D., Thome J.C. et al. Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J. Rheumatol. 1995- 22(2): 241−5.
- Abu-Sharka, M, Gladman, DD. Aetiopathogenesis of psoriatic arthritis. Rheumatology Reviews 1994- 3: 1−4.
- Aguierre M.A., Velez A., Romero M. et al. Gynecomastia and sexual impotence associated with methotrexate treatment. J. Rheumatol. 2002- 29: 17 934.
- Ahmed Q., Chung-Park M., Mustafa M.- Khan M.A. Psoriatic spondyloarthropathy with secondary amyloidosis. J. Pheumatol. 1996- 23: 110 710.
- American association of endocrinoiogists (AACE) medical guidelines for the prevention and treatment of postmenopausal g isteoporosis: 2001 edition, with selected updates for 2003 // Endocr Pract 2003. — Vol. 9, № 6. — P. 544−564.
- Ammann R Rizzoli R, Deloffre P, Tsouderos Y Meyer JM, Bonjour
- JR The increase in vertebral bone mass induced in intact rats, by long-term administration of the strontium salt S-12 911 is directly correlated with5 vertebral bone strength. Osteoporos Int 1996−6(Sl):259(Ptu706).
- Amor B. Data management in spondyloarthropathies. Rheumatology in Europe. 1996- 25:92−5.
- Anderson D.M., Marashovsky E., Billingsley W.L., Dougall W.C., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function. Nature, 1997−390:175−179.
- Antoni C, Smolen J. The infliximab multinational psoriatic arthritis controlled trial (IMPACT): 61th Annual Meeting of Am. Acad, of Dermatology. San Francisco. 2003- 31: 73−6.
- Arnett, F.C., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988- 31:315−324.
- Assouere M.N., Belhadja H., Albes B. Psoriasis: relationships, between joint and skin disease // Ann. Dermatol. Venerol.— 2002.— Vol. 129.— P: 1S749.
- Azuma, Y., Kaji, K., Katogi, R., Takeshita, S., and Kudo, A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 2000- 275:4858−4864.
- Baek H.J., Yoo CD., Shin K.C. et al. Spondylitis in the most common pattern of psoriatic arthritis in Korea. Rheumatol. Int. 2000- 19: 89−94.
- Baron R, Tsouderos Y In vitro effects of SI2911−2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002−450 :11−17.
- Battistone M.J., Manaster B.J., Reda D.J., Clegg D.O. The prevalence of sacroiliitis in psoriatic arthritis: A new perspectives from large, multicenter cohort. A department of Veterans Affairs Cooperative Study. Skeletal Radiol. 1999- 28: 196−201.
- Bhalerao, J, Bowcock, AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum. Mol. Genet. 1998- 7: 1537−45.
- Bianchi L., Paro Vidolin A., Neto I., Esposito M. Efficacy and safety of infliximab in the treatment of severe plaque or arthropathic psoriasis // Ann. Dermatol. Venerol.—2002. Vol. 129.—P. 1S751.
- Boivin G, DeLoffre P, Perrat B et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12 911) administration. J Bone Miner Res 1996−11:1302−1311.
- Bologna C, Endo L., Anaya L.M. et al, Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum. 1994- 37- 12: 1770−3.
- Braun J., Sieper J. Role of novel biological therapies in psoriatic arthritis: effects on joint and skin. BioDrugs. 2003- 17: 87−99.
- Brockbank J.E., Schentag C, Rosen C. et al. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medicine clinical attendees. Arthritis Rheum. 2001- 44,94−96.
- Brockbank J.E., Stein M, Schentag CT., Gladman D.D. Characteristics of dactylitis in psoriatic arthritis. Arthritis Rheum. 2000- 43, Suppl.: 104. Bruce I.N., Simian AJ. The aetiology of psoriatic arthritis. Rheumatology (Oxford). 2001- 40: 363−6.
- Bromley, M., and Woolley, D.E. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum. 1984- 27:968−975.
- Brown¦ JR., Josse R.G. 2002 clinical practice guidelines and management of osteoporosis in Canada // CMAJ. 2001 ~ Vol. 167, № 10. Suppl. -P. S1-S34.
- Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprogenin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev., 1998−12:1260−1268.
- Bywaters, E.G., and Dixon, A.S. Paravertebral ossification in psoriatic arthritis. Ann. Rheum. Dis. 1965.- 24:313−331.
- Canalis E, Hott M, Deloffre P, Tsouderos Y Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996 -18 :517−523.
- Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999−353:878−82.
- Chapuy MC, Arlot M, Delmas P, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ, 1994, 308:1081−1082.
- Christopher T. Ritchlinl, 2, Sally A. Haas-Smithl, 2, Ping Li2, David G. Hicks3 and Edward M. Schwarz2 Mechanisms of TNF-a- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis J. Clin. Invest, 2003 111(6): 821−831.
- Collin-Osdoby, P., et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 2001−276:20 659−20 672.
- Committee for Proprietary Medicinal Products. Note for Guidance on Post Menopausal Osteoporosis in Women Rev. 1 (CPMP adopted January2001).
- Costello P, Bresnihan B, O’Farrelly C, FitzGerald O. Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 1999−26:1117−24.
- Costello PJ, Winchester RJ, Curran SA, Peterson KS, Kane DJ, Bresnihan B, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 2001−166:2878−86.
- Coulombe J, Faure H, Robin B, Tsouderos Y Ruat M. Activation of the rat and mouse cation-sensing receptor by strontium ranelate and its modulation by extracellular calcium. Osteoporos Int 2002- 13 (suppl 1): P70.
- Creamer D, Jaggar R, Allen M, Bicknell R, Barker J. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 1997−137:851−5.
- Cummings RS, Melton LJ 3rd. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002−359:1761−7.
- Danning, C.L., et al. Macrophage-derived cytokine and nuclear factor kappa B p65 expression in synovial membrane and skin of patients with" psoriatic arthritis. Arthritis Rheum. 2000- 43:1244−1256.
- Demulder, A., Takahashi, S., Singer, F.R., Hosking, D.J., and Roodman, G.D. Abnormalities in- osteoclast precursors and marrow accessory cells in Paget’s disease. Endocrinology. 1993- 133:1978—1982.
- Donaldson LJ- Gook Aj Thomson-RG. Incidence of fractures in a^ geographically defined population. J Epidemiol Community Health 1990: 44:241−245.
- Downs R.W. Jr. Bell N.H. Ettinger M.P. etal. Comparison of alendronate and intranasal1 calcitonin for treatment of osteoporosis in postmenopausal women J. Clin: Endocrinol- Metab. — 20 001— Vol 85. — P. 1783—1788.
- Edwards CJ, Arden NK, Fisher D, et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology 2005-
- Espinoza LRZakraqui L, Espinoza CG, et al. Psoriatic arthntis: clinical response and side effects to. methotrexate therapy. J. Rheumatol 1992- 19-¦872″
- Faust, J., et al. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J. Cell. Biochem. 1999- 72:67−80.
- FDA, Draft, Guidance Postmenopausal Osteoporosis. Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis (Issued 4/1994).
- Fearon U., Veal DJ. Pathogenesis of psoriatic arthritis. Clin. Exp. Dermatol. 2001- 26: 333−7.
- Fedotov V.P., DyudyunA.D., Svyatenko T.V. Psoriatic arthritis and chlamidial infection correlation and interdependency // JEADV.— 2000.— Vol. 14.—P. 247.
- Frediani B, Allegri A, Falsetti P, et al. Bone mineral4 density in patients with psoriatic arthritis. J Rheumatol 2001−28:13 8−43.
- Fujikawa, Y., Sabokbar, A., Neale, S., and Athanasou, N.A. Human osteoclast formation and bone resorption. by monocytes and synovial macrophages in rheumatoid arthritis. Ann. Rheum. Dis. 1996- 55: 816−822.
- Geilen C.C., Orfanos C.E. Standart and innovative therapy of psoriasis. Clin. Exp. Rheumatol. 2002- 20, Suppl: 28: S81−7.
- G enant H., Wu C/.Kuijik C., Nevitt M. Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res, 1993, 8, 137−1148.
- Genant HK, Wu CY van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993 :8> :1137−48.
- Gladman D.D. Effectiveness of psoriatic arthritis therapies. Semin. Arthritis Rheum. 2003- 33: 29−37.
- Gladman D.D., Brockbank J. Psoriatic arthritis. Expert Opin Investig. Drugs 2000- 9: 1511−22.
- Gladman D.D., Farewell V.T., Pellett F. et al. HLA is a candidate region for psoriatic arthritis. Evidence for excessive HLA sharing in sibling pairs. Hum. Immunol. 2003- 64: 887−92.
- Gladman DD, Anhorn KA, Schachter RK, Mevart H. HLA antigens in psoriatic arthritis. J Rheumatol 1986−13:586−92.
- Gladman, D.D. Psoriatic arthritis. 1998. Rheum. Dis. Clin. North Am. 24:829−844.
- Goedkoop A.Y., Dinant H.Y., Van Kuijk A.W. Alefacept improves psoriatic arthritis and reduces synovial inflammatory infiltrate // Ann. Dermatol. Venerol.—2002.—Vol. 129.—P. 1S756.
- Gori, F., et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology. 2000- 141:4768−4776.
- Gottieb A., Burge D., Wanke L. Etanercept improves healthrelated quality of life in psoriatic arthritis patients // Ann. Dermatol. Venerol.— 2002.— Vol. 129.—P. 1S756.
- Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995- 1:442−7.
- Gravallese, E.M., and Goldring, S.R. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res. 2000- 2 :33—37.
- Gravallese, E.M., et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am. J. Pathol. 1998- 152:943−951.
- Gravallese, E.M., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum. 2000- 43 :250—258.
- Gregoretti, M.G., et al. Osteoclast precursors circulate in the peripheral blood of patients with aggressive multiple myeloma. Leukemia. 1995- 9:1392−1397.
- Helliwell, P., Marchesoni, A., Peters, M., Barker, M., and Wright, V. A re-evaluation of the osteoarticular manifestations of psoriasis. Br. J. Rheumatol, 1991. 30:339−345.
- Hoehler Т., Marker-Hermann E. Psoriatic arthritis: clinical aspects, genetics and the role of T cells. Curr. Opin. Rheumatol. 2001- 13: 273−9.
- Hofbauer, L.C., and Heufelder, A.E. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum. 2001- 44:253−259.
- Hofbauer, L.C., and Heufelder, A.E. The role of receptor activator of nuclear factor-kappa В ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J. Clin. Endocrinol. Metab. 2000- 85:23 552 363.
- Horowitz M.C., Xi Y., Wilson К., Kacena M.A. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands// Cytokine Growth Factor Rev.- 2001.-V.12, № 1.-P.9−18
- Institute for Clinical Systems Improvement (ICSI) Health Care Guideline: Diagnosis and Treatment of Osteoporosis. 3rd edition* July 2004. www. icsLorg (дата последнего посещения 11.10.2004).
- Jackson C.G. Immunomodulating drugs in the management of psoriatic arthritis. Am. J. Clin. Dermatol. 2001- 2(6): 367−75.
- Ji, H., Ohmura, K., Mahmood, U., et al (2002) Arthritis critically dependent on innate immune system players. Immunity 16, 157−159.
- Jiang Y., Zhao J.J., Mitlak B.H. et al. Recombinant human parathyroid hormone (1−34) Teriparatide. improves both cortical and cancellous bone structure // J. Bone Miner. Res. 2003. — Vol. 18. — P. 1932−1941.
- Jolly E.E., Bjarnason N.H., Neven P., Plouffe L. Jr et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking ratoxifene for 5 years. // Menopause. 2003. — Vol. — 10 #4. — P.337−344.
- Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum 2003−48:1676−85.
- Khan M.A., Gladman D.D. Clinical and radiological changes during psoriatic arthritis disease progression. J. Rheumatol. 2003- 30: 1022−6.
- Kim WJ, Laterza OF, Hock KG, Pierson-Perry JF, Kaminski DM, Mesguich M, et al. Performance of a revised cardiac troponin method that minimizes interferences from heterophilic antibodies. Clin Chem 2002−48:1028−1034.
- Kobayashi, K., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKLRANK interaction. J. Exp. Med. 2000- 191:275−286.
- Kong Y-Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymp-node organogenesis. Nature, 1999−397:315−323.
- Kong, Y.Y., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Neurosurgery. 1999- 402:304−309.
- Koo T., Nagy Z., Sesztak M. et al. Subsets in psoriatic arthritis formed by cluster analysis. Clin. Rheumatol. 2001- 20: 36−43.
- Kotake, S., et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destructions rheumatoid arthritis patients. Arthritis Rheum. 2001- 44:1003−1012.
- Krueger G., Lebwohl M., Gottlieb A.B., Mease A J. Etanercept improves psoriasis in patient with psoriatic arthritis: results of a phase 3 multicenter clinical trial // Ann. Dermatol. Veneroll— 2002.— Vol. 129.— P. 1S760.
- Lacaille D, Stein HB, Raboud J, Klinkhoff AV. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol 2000- 27:1922−7.
- Lacey, D.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998- 93:165−176.
- Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondylarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001- 60:316−321.
- Lam, J., et al. TNF-a induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 2000- 106:1481−1488.
- Marguerie L, Flipo RM, Grardel B, Beaurain D, Duquesnoy B, Delcambre B. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine 2002- 69:275−81.
- Markham T, Fearon U, Mullan R, et al. Anti-TNF alpha therapy in psoriasisxlinical and angiogenic responses. Br J Dermatol. 2003−143(suppl 59):40.
- Martel, W., Hayes, J.T., and Duff, I.F. The pattern of bone erosion in the hand and wrist in rheumatoid arthrits. Radiology. 1965- 84:204−208.
- Marzo-Ortega, H., McGonagle, D., O’Connor, P., and Emery, P. Efficacy of etanercept in the treatment of the entheseal* pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum. 2001- 44:2112−2117.
- Massey, H.M., and Flanagan, A.M. Human osteoclasts derive from CD14-positive monocytes. Br. J. Haematol. 1999- 106:167−170.
- McGowan, N.W., Walker, E.J., Macpherson, H., Ralston, S.H., and Helfrich, M.H. Cytokine-activated endothelium recruits osteoclast precursors. Endocrinology. 2001- 142:1678−1681.
- Mease, P.J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000- 356:385−390.
- Mease, P.J., Goffe, B., Metz, J., and Vanderstoep, A. Embrel (etanercept) in patients with psoriatic arthritis and psoriasis. Arthritis Rheum. 1999- 42:377. (Abstr.)
- Meunier P, Slosman D., Delmas P. et al. Strontium ranelate: Dose dependent effects in established postmenopausal vertebral osteoporosis: A 2 year randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 2002, 87, 20 602 066.
- Meunier PX Sebert J.L., Reginster J. Y etal Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in ostmenopausal osteoporosis: the FAVO Study I I Qsteoporos. Int— 1998 VoL 8. P. 4−12.
- Moll, J.M., Wright V. Psoriatic arthritis. Semin. Arthritis Rheum. 1973−3:55−78.
- Myers, D.E., et al. Expression of functional RANK on mature rat and human osteoclasts. FEBS Lett. 1999- 463:295−300.
- Nakagawa, N., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem. Biophys. Res. Commun. 1998- 253:395−400.
- Neer R.M., Arnaud C.D., Zanchetta J.R. et al. The effect of parathyroid hormone (1−34) on fractures and bone mineral density in postmenopausal women with osteoporosis // N. Engl. J. Med. — 2001. Vol. 344. #19.-P. 1434−1441.
- Nicholson, G.C., et al. Induction of osteoclasts from CD14-positive human peripheral blood mononuclear cells by receptor activator of nuclear factor kappaB ligand (RANKL). Clin. Sci. 2000- 99:133−140.
- NIH Consensus Development Conference on Osteoporosis: Prevention, Diagnosis and Therapy // JAMA. 2000. — Vol. 287. — P.785−795
- Niki Y, Yamada H, Seki S, et al.: Macrophage- and neutrophil-dominant arthritis in human IL-1 alpha transgenic mice. J Clin Invest 2001, 107:1127- 1135.
- Pagani F, Bonetti G, Stefmi F, Cuccia C, Panteghini M. Serum and plasma samples for ACS: Systems cardiac markers. Clin Chem 2000−46:1020−1022.
- Paiva ES, Macaluso DC, Edwards A, et al.: Characterization of uveitisin patients with psoriatic arthritis. Ann Rheum Dis 2000, 59:67−70.
- Papadopoulos NG, Alamanos Y, Papadopoulos IA, et al. Disease modifying antirheumatic drugs in early rheumatoid- arthritis: a, long term observational study. J Rheumatol 2002- 29L 261−266
- Partsch, G., et al. T cell derived cytokines in psoriatic arthritis synovial fluids. Ann. Rheum. Dis. 1998- 57:691−693.
- Pettit, A.R., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 2001- 159:1689−1699.
- Pi M, Quarles LD. A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. J Bone Miner Res 2004 -19: 862−9.
- Raffayova H, Rovensky J, Malis F. Treatment with cyclosporin in patients with psoriatic. arthritis. Int J Clin Pharmacol Res. 2000- 20:1−11.
- Redlich, K., et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum. 2002- 46:785−792.
- Reece, R.J., Canete, J.D., Parsons, W.J., Emery, P., and Veale, D.J. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum. 1999- 42:1481−1484.
- Reginster J., Deroisy R., Dougados M. et al. Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two year, double blind, dose ranging, placebo controlled trial. Osteopor. Int., 2002, 13, 925 931.
- Reginster JY Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, doublemasked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002- 13:925−31.
- Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: tropos study. J Clin Endocrinol Metab 2005, 34:73−8.
- Rejnmark I, Vestvrgaant P., Toffetig C. L, et at. Response rates to estrogen treatment in perimenopausal women: 5-year data from The Danish sreoporosis Prevention Study (DOPS) // Maturitas. 2004. — - Vol. 48. — 307 — 320.
- Resnick, D., and Niwayama, G. Psoriatic arthritis. In Bone and joint imaging. D. Resnick, editor. W.B. Saunders Co. Philadelphia, Pennsylvania, USA, 1989. 320−328.
- Resnick, D., and Niwayama, G. Psoriatic arthritis. In Diagnosis of bone and joint disorders. D. Resnick and G. Niwayama, editors. W.B. Saunders Co. Philadelphia, Pennsylvania, USA., 1981. 1103−1109.
- Ritchlin С, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998−25:1544−52.
- Ritchlin C. Newer therapeutic approaches: spondylarthritis and uveitis // Rheum Dis Clin North Am 2006- 32: 75−90.
- Ritchlin, C., and Haas-Smith, S.A. Expression of interleukin 10 mRNA and protein by synovial fibroblastoid cells. J. Rheumatol. 2001- 28:698 705.
- Ritchlin, C., et al. Patterns of cytokine production in psoriatic synovium. J. Rheumatol. 1998- 25:1544−1552.
- Salem A., Kady В., Tarshouby W., Olama S. HLA antigens in patients with psoriatic arthritis // Ann. Dermatol. Venerol.— 2002.— Vol. 129.— P. 1S767.
- Salvarani, C., Cantini, F., Olivieri, I. et al. (2002) Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. Journal of Rheumatology 27(6), 1470−1476.
- Scottish Intercollegiate Guidelines Network (SIGN) # -Management of osteoporosis: a national clinical guideline, June 2003. www.sign.ac.uk (дата последнего посещения 11.10.2004).
- Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002−359: 1841−1850.
- Shalhoub, V., et al. Characterization of osteoclast precursors in human blood. Br. J. Haematol. 2000- 111:501−512.
- Shigeyama, Y., et al. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum. 2000- 43:2523−2530.
- Simoner W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1998−93: 165−176.
- Simonet, W.S., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997- 89:309−319.
- Suda, T., et al. Modulation of osteoclast differentiationandfunction by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 1999- 20:345−357.
- Takahashi N, Sasaki N, Tsouderos Y SudaT. S12911−2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003-! 8 :1082−87.
- Takayanagi, H., et al. A new mechanism of bone destruction in. rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem. Biophys. Res. Commun. 1997- 240:279−286.
- Takayanagi, H-, et al. T-cell-mediated regulation of osteoclastogenesis by. signalling cross-talk between RANKL and IEN-gamma. Neurosurgery. 2000- 408:600−605.
- Tassiulas I, Duncan SR, Centola M et al. Clonal characteristics of T cell infiltrates in skin Clin Diagn Lab Immunol 1999- 6:85−8.
- Teitelbaum, S.L. Bone resorption by osteoclasts. Science: 2000.- 289:1504−1508.
- Toritsuka, Y., et al. Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis. J. Rheumatol. 1997- 24:1690−1696.
- Ujfalussy I, Koo E, Sesztak M, Gergely P. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. Z Rheumatol. 2003 Apr-62(2): 155−60.t. ¦ .
- Uusi-Rasi K, Beck T. J., Sievunen H: et jt. Associations* of Hormonereplacement therapy, with bone structure and physical performance among-postmenopausal women // Bone. 2003. — Vol. 32.—P. 704 710. ¦
- Valimaki MJ., Laitinen K.A., Tahtela R.K. et al. The effects- of transdermal- estrogen therapy on bone mass and turnover in early postmenopausal smokers, controlled study // Am: J. Obstet. Gynecol. 2003. — Vol. 189- P. 12 131 220.
- Veale D, Rogers S, Fitzgerald O. Immunolbcalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skin. Br J Dermatol 1995−132:32−8. = •
- Veale DJ, Barnes L, Rogers S- FitzGerald O- Immunohistochemical markers for arthritis-in psoriasis. Ann? RHeum Dis 1994−53:450-L4.
- Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991- 90:711−6.